23andme.com снижает цены на анализ ДНК с $300 до $100
We have some great news that we’re excited to share with our fans - starting today, 23andMe is just $99! The new price still includes the complete set of both health and ancestry results, and continues to be subscription-free.
Your 23andMe results can empower you to make informed health decisions and learn more about your ancestry. We hope this new price will enable your family and friends to enjoy the same discoveries.
Happy Holidays,
The 23andMe Team
Активное участие в финансировании этого банкета примет известный российский инвестор Юрий Мильнер:
MOUNTAIN VIEW, Calif. - December 11, 2012 - 23andMe. Inc., the leading personal genetics company, today announced it has raised more than $50 million in a Series D financing. Participants in the financing include Yuri Milner, a new investor, as well as existing investors Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. This investment will help the company achieve its growth goal of one million customers.
Expanding the company’s ability to reach and serve one million individuals supports 23andMe’s goal to revolutionize health and wellness. It also will accelerate 23andMe’s ability to create a powerful platform that enables researchers around the globe to make meaningful discoveries significantly faster than is currently possible. With this expansion, 23andMe, which currently has more than 180,000 customers, will aim to:
- Enable groundbreaking research by creating an exponentially larger collective of actively engaged, genotyped individuals;
- Help accelerate development of new treatments;
- Improve understanding of wellness and disease prevention; and
- Broaden access for people seeking to manage their health and well-being through direct access and greater understanding of their own genetic data.
“A community of one million actively engaged individuals will be transformational for research. A community of this magnitude will improve researchers’ ability to quickly answer questions about genetic function and the role of environmental factors. In addition, it will enable researchers to understand medication efficacy and side effects, in both medications that exist today and medications are that are in development,” Wojcicki added.
Your 23andMe results can empower you to make informed health decisions and learn more about your ancestry. We hope this new price will enable your family and friends to enjoy the same discoveries.
Happy Holidays,
The 23andMe Team
Активное участие в финансировании этого банкета примет известный российский инвестор Юрий Мильнер:
MOUNTAIN VIEW, Calif. - December 11, 2012 - 23andMe. Inc., the leading personal genetics company, today announced it has raised more than $50 million in a Series D financing. Participants in the financing include Yuri Milner, a new investor, as well as existing investors Sergey Brin, 23andMe CEO Anne Wojcicki, New Enterprise Associates, Google Ventures and MPM Capital. This investment will help the company achieve its growth goal of one million customers.
Expanding the company’s ability to reach and serve one million individuals supports 23andMe’s goal to revolutionize health and wellness. It also will accelerate 23andMe’s ability to create a powerful platform that enables researchers around the globe to make meaningful discoveries significantly faster than is currently possible. With this expansion, 23andMe, which currently has more than 180,000 customers, will aim to:
- Enable groundbreaking research by creating an exponentially larger collective of actively engaged, genotyped individuals;
- Help accelerate development of new treatments;
- Improve understanding of wellness and disease prevention; and
- Broaden access for people seeking to manage their health and well-being through direct access and greater understanding of their own genetic data.
“A community of one million actively engaged individuals will be transformational for research. A community of this magnitude will improve researchers’ ability to quickly answer questions about genetic function and the role of environmental factors. In addition, it will enable researchers to understand medication efficacy and side effects, in both medications that exist today and medications are that are in development,” Wojcicki added.